{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:32Z","timestamp":1782950432639,"version":"3.54.5"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["T32CA154274"],"award-info":[{"award-number":["T32CA154274"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA271540"],"award-info":[{"award-number":["1R01CA271540"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["5R01CA233585 \u2013 05"],"award-info":[{"award-number":["5R01CA233585 \u2013 05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA273956"],"award-info":[{"award-number":["U54CA273956"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0296"],"award-info":[{"award-number":["W81XWH-21-1-0296"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Movember Foundation-Distinguished Gentlemen\u2019s Ride-Prostate Cancer Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41391-025-01041-z","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:57:49Z","timestamp":1760191069000},"page":"282-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrating systemic therapy and metastasis-directed therapy in oligometastatic hormone-sensitive prostate cancer"],"prefix":"10.1038","volume":"29","author":[{"given":"Xiaolei","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarey H.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian F.","family":"Chapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-0923","authenticated-orcid":false,"given":"Ana","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-7732","authenticated-orcid":false,"given":"Sumit K.","family":"Subudhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuoc T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4725-2937","authenticated-orcid":false,"given":"Ryan J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Deek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3631-9163","authenticated-orcid":false,"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Bylund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheal","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7012-1754","authenticated-orcid":false,"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4021-5909","authenticated-orcid":false,"given":"Philip","family":"Sutera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"1041_CR1","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.2147\/OTT.S228355","volume":"13","author":"ME Hall","year":"2020","unstructured":"Hall ME, Huelster HL, Luckenbaugh AN, Laviana AA, Keegan KA, Klaassen Z, et al. Metastatic hormone-sensitive prostate cancer: current perspective on the evolving therapeutic landscape. Onco Targets Ther. 2020;13:3571\u201381.","journal-title":"Onco Targets Ther"},{"key":"1041_CR2","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974\u201386.","journal-title":"J Clin Oncol"},{"key":"1041_CR3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163\u201377.","journal-title":"Lancet"},{"key":"1041_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13\u201324.","journal-title":"N Engl J Med"},{"key":"1041_CR5","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","volume":"42","author":"F Saad","year":"2024","unstructured":"Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol. 2024;42:4271\u201381.","journal-title":"J Clin Oncol"},{"key":"1041_CR6","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389:1453\u201365.","journal-title":"N Engl J Med"},{"key":"1041_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","volume":"10","author":"M Hussain","year":"2024","unstructured":"Hussain M, Fizazi K, Shore ND, Heidegger I, Smith MR, Tombal B, et al. Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review. JAMA Oncol. 2024;10:807\u201320.","journal-title":"JAMA Oncol"},{"key":"1041_CR8","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1097\/JU.0000000000002121","volume":"206","author":"CJ Ryan","year":"2021","unstructured":"Ryan CJ, Ke X, Lafeuille MH, Romdhani H, Kinkead F, Lefebvre P, et al. Management of patients with metastatic castration-sensitive prostate cancer in the real-world setting in the United States. J Urol. 2021;206:1420\u20139.","journal-title":"J Urol"},{"key":"1041_CR9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11912-024-01509-6","volume":"26","author":"G Grisay","year":"2024","unstructured":"Grisay G, Lavaud P, Fizazi K. Current systemic therapy in men with metastatic castration-sensitive prostate cancer. Curr Oncol Rep. 2024;26:488\u201395.","journal-title":"Curr Oncol Rep."},{"key":"1041_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8\u201310.","journal-title":"J Clin Oncol"},{"key":"1041_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/jamaoncol.2020.6146","volume":"7","author":"EJ Lehrer","year":"2021","unstructured":"Lehrer EJ, Singh R, Wang M, Chinchilli VM, Trifiletti DM, Ost P, et al. Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis. JAMA Oncol. 2021;7:92\u2013106.","journal-title":"JAMA Oncol"},{"key":"1041_CR12","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051\u20138.","journal-title":"Lancet"},{"key":"1041_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1200\/JCO.2020.38.6_suppl.10","volume":"38","author":"P Ost","year":"2020","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, Bruycker AD, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-year results of a randomized phase II trial. J Clin Oncol. 2020;38:10.","journal-title":"J Clin Oncol"},{"key":"1041_CR14","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","volume":"37","author":"DR Gomez","year":"2019","unstructured":"Gomez DR, Tang C, Zhang J, Blumenschein GR Jr., Hernandez M, Lee JJ, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37:1558\u201365.","journal-title":"J Clin Oncol"},{"key":"1041_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5977-6","volume":"19","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Correa RJM, Schneiders F, Haasbeek CJA, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4\u201310 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019;19:816.","journal-title":"BMC Cancer"},{"key":"1041_CR16","doi-asserted-by":"publisher","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","volume":"4","author":"P Iyengar","year":"2018","unstructured":"Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4:e173501.","journal-title":"JAMA Oncol"},{"key":"1041_CR17","doi-asserted-by":"crossref","unstructured":"Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst. 2017;109:djx015.","DOI":"10.1093\/jnci\/djx015"},{"key":"1041_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2967\/jnumed.121.263684","volume":"63","author":"P Sutera","year":"2022","unstructured":"Sutera P, Phillips RM, Deek M, Ozyigit G, Onal C, Tran PT. The promise of metastasis-directed therapy for oligometastatic prostate cancer: going beneath the surface with molecular Imaging. J Nucl Med. 2022;63:339\u201341.","journal-title":"J Nucl Med"},{"key":"1041_CR19","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/JU.0000000000000800","volume":"204","author":"N Fossati","year":"2020","unstructured":"Fossati N, Scarcella S, Gandaglia G, Suardi N, Robesti D, Boeri L, et al. Underestimation of positron emission tomography\/computerized tomography in assessing tumor burden in prostate cancer nodal recurrence: head-to-head comparison of (68)Ga-PSMA and (11)C-choline in a large, multi-institutional series of extended salvage lymph node dissections. J Urol. 2020;204:296\u2013302.","journal-title":"J Urol"},{"key":"1041_CR20","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.jtho.2017.06.015","volume":"12","author":"EM Gore","year":"2017","unstructured":"Gore EM, Hu C, Sun AY, Grimm DF, Ramalingam SS, Dunlap NE, et al. Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ED SCLC): NRG Oncology RTOG 0937. J Thorac Oncol. 2017;12:1561\u201370.","journal-title":"J Thorac Oncol"},{"key":"1041_CR21","doi-asserted-by":"crossref","unstructured":"Chmura SJ, Winter KA, Woodward WA, Borges VF, Salama JK, Al-Hallaq HA, et al. NRG-BR002: a phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). J Clin Oncol. 2022;40:1007\u20131007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007"},{"key":"1041_CR22","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ijrobp.2024.10.030","volume":"121","author":"JP Reddy","year":"2025","unstructured":"Reddy JP, Sherry AD, Fellman B, Liu S, Bathala T, Haymaker C, et al. Adding metastasis-directed therapy to standard-of-care systemic therapy for oligometastatic breast cancer (EXTEND): a multicenter, randomized phase 2 trial. Int J Radiat Oncol Biol Phys. 2025;121:885\u201393.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.","journal-title":"N Engl J Med"},{"key":"1041_CR24","doi-asserted-by":"crossref","unstructured":"Sutera P, Van Der Eecken K, Kishan AU, Hamid A, Grist E, Attard G, et al. Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. Prostate Cancer Prostatic Dis. 2022;25:713\u201319.","DOI":"10.1038\/s41391-021-00484-4"},{"key":"1041_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.euo.2024.05.011","volume":"8","author":"P Sutera","year":"2025","unstructured":"Sutera P, Song Y, Shetty AC, English K, Van der Eecken K, Guler OC, et al. Genomic determinants associated with modes of progression and patterns of failure in metachronous oligometastatic castration-sensitive prostate cancer. Eur Urol Oncol. 2025;8:111\u20138.","journal-title":"Eur Urol Oncol"},{"key":"1041_CR26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.eururo.2020.12.040","volume":"80","author":"MP Deek","year":"2021","unstructured":"Deek MP, Van der Eecken K, Phillips R, Parikh NR, Isaacsson Velho P, Lotan TL, et al. The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited. Eur Urol. 2021;80:632\u201340.","journal-title":"Eur Urol"},{"key":"1041_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.eururo.2018.11.045","volume":"76","author":"AA Hamid","year":"2019","unstructured":"Hamid AA, Gray KP, Shaw G, MacConaill LE, Evan C, Bernard B, et al. Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer. Eur Urol. 2019;76:89\u201397.","journal-title":"Eur Urol"},{"key":"1041_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/JCO.23.00753","volume":"42","author":"EF Gillespie","year":"2024","unstructured":"Gillespie EF, Yang JC, Mathis NJ, Marine CB, White C, Zhang Z, et al. Prophylactic radiation therapy versus standard of care for patients with high-risk asymptomatic bone metastases: a multicenter, randomized phase II clinical trial. J Clin Oncol. 2024;42:38\u201346.","journal-title":"J Clin Oncol"},{"key":"1041_CR29","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6:650\u20139.","journal-title":"JAMA Oncol"},{"key":"1041_CR30","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1200\/JCO-25-00131","volume":"43","author":"JH Wang","year":"2025","unstructured":"Wang JH, Sherry AD, Bazyar S, Sutera P, Radwan N, Phillips RM, et al. Outcomes of radium-223 and stereotactic ablative radiotherapy versus stereotactic ablative radiotherapy for oligometastatic prostate cancers: The RAVENS phase II randomized trial. J Clin Oncol. 2025;43:2059\u201368.","journal-title":"J Clin Oncol"},{"key":"1041_CR31","volume":"14","author":"E Nabrinsky","year":"2022","unstructured":"Nabrinsky E, Macklis J, Bitran J. A review of the abscopal effect in the era of immunotherapy. Cureus. 2022;14:e29620.","journal-title":"Cureus"},{"key":"1041_CR32","doi-asserted-by":"crossref","unstructured":"Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, et al. Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial. JAMA Oncol. 2023;9:825\u201334.","DOI":"10.1001\/jamaoncol.2023.0161"},{"key":"1041_CR33","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737\u201346.","journal-title":"N Engl J Med"},{"key":"1041_CR34","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36:1080\u20137.","journal-title":"J Clin Oncol"},{"key":"1041_CR35","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352\u201360.","journal-title":"N Engl J Med"},{"key":"1041_CR36","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338\u201351.","journal-title":"N Engl J Med"},{"key":"1041_CR37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121\u201331.","journal-title":"N Engl J Med"},{"key":"1041_CR38","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/JCO.2025.43.16_suppl.5005","volume":"43","author":"AJ Armstrong","year":"2025","unstructured":"Armstrong AJ, Petrylak DP, Shore ND, Szmulewitz RZ, Holzbeierlein J, Villers A, et al. ARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC). J Clin Oncol. 2025;43:5005.","journal-title":"J Clin Oncol"},{"key":"1041_CR39","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","volume":"76","author":"AP Hoyle","year":"2019","unstructured":"Hoyle AP, Ali A, James ND, Cook A, Parker CC, de Bono JS, et al. Abiraterone in \u201chigh-\u201c and \u201clow-risk\u201d metastatic hormone-sensitive prostate cancer. Eur Urol. 2019;76:719\u201328.","journal-title":"Eur Urol"},{"key":"1041_CR40","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.eururo.2021.05.016","volume":"80","author":"CJ Sweeney","year":"2021","unstructured":"Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy. Eur Urol. 2021;80:275\u20139.","journal-title":"Eur Urol"},{"key":"1041_CR41","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","volume":"24","author":"CJ Sweeney","year":"2023","unstructured":"Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:323\u201334.","journal-title":"Lancet Oncol"},{"key":"1041_CR42","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.eururo.2023.04.002","volume":"84","author":"AJ Armstrong","year":"2023","unstructured":"Armstrong AJ, Iguchi T, Azad AA, Villers A, Alekseev B, Petrylak DP, et al. The Efficacy of enzalutamide plus androgen deprivation therapy in oligometastatic hormone-sensitive prostate cancer: a post hoc analysis of ARCHES. Eur Urol. 2023;84:229\u201341.","journal-title":"Eur Urol"},{"key":"1041_CR43","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Flechon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2022;399:1695\u2013707.","journal-title":"Lancet"},{"key":"1041_CR44","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386:1132\u201342.","journal-title":"N Engl J Med"},{"key":"1041_CR45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","volume":"87","author":"S Gillessen","year":"2025","unstructured":"Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, et al. Management of patients with advanced prostate cancer. Report from the 2024 advanced prostate cancer consensus conference (APCCC). Eur Urol. 2025;87:157\u2013216.","journal-title":"Eur Urol"},{"key":"1041_CR46","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.annonc.2023.04.515","volume":"34","author":"PA Sutera","year":"2023","unstructured":"Sutera PA, Shetty AC, Hakansson A, Van der Eecken K, Song Y, Liu Y, et al. Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer. Ann Oncol. 2023;34:605\u201314.","journal-title":"Ann Oncol"},{"key":"1041_CR47","unstructured":"National Comprehensive Cancer Network. 2025. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Prostate Cancer, Version 2.2025. Accessed September 7, 2025."},{"key":"1041_CR48","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/14737140.2025.2509760","volume":"25","author":"G Ingrosso","year":"2025","unstructured":"Ingrosso G, Lancia A, Bardoscia L, Becherini C, Bottero M, Bertini N, et al. Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer. Expert Rev Anticancer Ther. 2025;25:741\u201354.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1041_CR49","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"LMS Boeve","year":"2019","unstructured":"Boeve LMS, Hulshof M, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2019;75:410\u20138.","journal-title":"Eur Urol"},{"key":"1041_CR50","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353\u201366.","journal-title":"Lancet"},{"key":"1041_CR51","doi-asserted-by":"publisher","first-page":"e1003998","DOI":"10.1371\/journal.pmed.1003998","volume":"19","author":"CC Parker","year":"2022","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Ali A, Amos CL, et al. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial. PLoS Med. 2022;19:e1003998.","journal-title":"PLoS Med"},{"key":"1041_CR52","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","volume":"76","author":"S Burdett","year":"2019","unstructured":"Burdett S, Boeve LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis. Eur Urol. 2019;76:115\u201324.","journal-title":"Eur Urol"},{"key":"1041_CR53","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","volume":"404","author":"A Bossi","year":"2024","unstructured":"Bossi A, Foulon S, Maldonado X, Sargos P, MacDermott R, Kelly P, et al. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2024;404:2065\u201376.","journal-title":"Lancet"},{"key":"1041_CR54","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid 2025. ISBN 978-94-92671-29-5."},{"key":"1041_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35612","volume":"131","author":"AH Bryce","year":"2025","unstructured":"Bryce AH, Agarwal N, Beltran H, Hussain MH, Sartor O, Shore N, et al. Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: consensus recommendations from the US prostate cancer conference 2024. Cancer. 2025;131:e35612.","journal-title":"Cancer"},{"key":"1041_CR56","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.euo.2023.07.014","volume":"7","author":"P Sutera","year":"2024","unstructured":"Sutera P, Shetty AC, Song Y, Hodges T, Hoang T, Rana Z, et al. Identification of a predictive genomic biomarker for prostate-directed therapy in synchronous low-volume metastatic castration-sensitive prostate cancer. Eur Urol Oncol. 2024;7:241\u20137.","journal-title":"Eur Urol Oncol"},{"key":"1041_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01662-7","volume":"39","author":"DK Reyes","year":"2022","unstructured":"Reyes DK, Trock BJ, Tran PT, Pavlovich CP, Deville C, Allaf ME, et al. Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. Med Oncol. 2022;39:63.","journal-title":"Med Oncol"},{"key":"1041_CR58","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-020-01385-7","volume":"37","author":"DK Reyes","year":"2020","unstructured":"Reyes DK, Rowe SP, Schaeffer EM, Allaf ME, Ross AE, Pavlovich CP, et al. Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer. Med Oncol. 2020;37:60.","journal-title":"Med Oncol"},{"key":"1041_CR59","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.eururo.2024.02.008","volume":"86","author":"NG Nickols","year":"2024","unstructured":"Nickols NG, Tsai S, Kane N, Tran S, Ghayouri L, Diaz-Perez S, et al. Systemic and tumor-directed therapy for oligometastatic prostate cancer: the SOLAR phase 2 trial in de novo oligometastatic prostate cancer. Eur Urol. 2024;86:190\u20133.","journal-title":"Eur Urol"},{"key":"1041_CR60","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11684-022-0939-9","volume":"17","author":"Y Chang","year":"2023","unstructured":"Chang Y, Zhao X, Xiao Y, Yan S, Xu W, Wang Y, et al. Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I\/II clinical trial. Front Med. 2023;17:231\u20139.","journal-title":"Front Med"},{"key":"1041_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74562-3","volume":"10","author":"C Reverberi","year":"2020","unstructured":"Reverberi C, Massaro M, Osti MF, Anzellini D, Marinelli L, Montalto A, et al. Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer. Sci Rep. 2020;10:17471.","journal-title":"Sci Rep."},{"key":"1041_CR62","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.ijrobp.2022.06.085","volume":"114","author":"C Hao","year":"2022","unstructured":"Hao C, Ladbury C, Lyou Y, Manoukian S, Ruel C, Frankel P, et al. Long-term outcomes of patients on a phase II prospective trial of oligometastatic hormone-sensitive prostate cancer treated with androgen deprivation and external beam radiation. Int J Radiat Oncol Biol Phys. 2022;114:705\u201310.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR63","doi-asserted-by":"crossref","unstructured":"Deek MP, Sutera P, Jing Y, Gao R, Rothman E, Day H, et al. Multi-institutional analysis of metastasis-directed therapy with or without androgen deprivation therapy in oligometastatic castration-sensitive prostate cancer. Eur Urol Oncol. 2024;7:1403\u201310.","DOI":"10.1016\/j.euo.2024.03.010"},{"key":"1041_CR64","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3857\/roj.2022.00101","volume":"40","author":"\u00c1L S\u00e1nchez-Iglesias","year":"2022","unstructured":"S\u00e1nchez-Iglesias \u00c1L, Morillo-Mac\u00edas V, Santaf\u00e9-Jim\u00e9nez A, Ferrer-Albiach C. Bone-only oligometastatic prostate cancer: can SABR improve outcomes? A single-center experience. Radiat Oncol J. 2022;40:192\u20139.","journal-title":"Radiat Oncol J"},{"key":"1041_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-021-01849-8","volume":"16","author":"P Rogowski","year":"2021","unstructured":"Rogowski P, Trapp C, von Bestenbostel R, Schmidt-Hegemann NS, Shi R, Ilhan H, et al. Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer. Radiat Oncol. 2021;16:125.","journal-title":"Radiat Oncol"},{"key":"1041_CR66","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446\u201353.","journal-title":"J Clin Oncol"},{"key":"1041_CR67","doi-asserted-by":"crossref","unstructured":"Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol. 2022;40:3377\u201382.","DOI":"10.1200\/JCO.2022.40.16_suppl.5025"},{"key":"1041_CR68","doi-asserted-by":"crossref","unstructured":"Wang JH, Sherry AD, Bazyar S, Sutera P, Radwan N, Phillips RM, et al. Outcomes of radium-223 and stereotactic ablative radiotherapy versus stereotactic ablative radiotherapy for oligometastatic prostate cancers: the RAVENS phase II randomized trial. J Clin Oncol. 2025;43:2059\u201368","DOI":"10.1200\/JCO-25-00131"},{"key":"1041_CR69","doi-asserted-by":"crossref","unstructured":"Sherry AD, Haymaker CL, Fellman BM, Bathala TK, Medina-Rosales MN, Liu S, et al. Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis with the updated intermittent ADT (iADT) basket and immune correlatives. J Clin Oncol. 2025;43:140\u2013140","DOI":"10.1200\/JCO.2025.43.5_suppl.140"},{"key":"1041_CR70","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","volume":"26","author":"G Marvaso","year":"2025","unstructured":"Marvaso G, Corrao G, Zaffaroni M, Vincini MG, Lorubbio C, Gandini S, et al. ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial. Lancet Oncol. 2025;26:300\u201311.","journal-title":"Lancet Oncol"},{"key":"1041_CR71","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","volume":"26","author":"P Ost","year":"2025","unstructured":"Ost P, Siva S, Brabrand S, Dirix P, Liefhooghe N, Otte FX, et al. Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial. Lancet Oncol. 2025;26:695\u2013706.","journal-title":"Lancet Oncol"},{"key":"1041_CR72","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1200\/JCO.23.00985","volume":"41","author":"G Francolini","year":"2023","unstructured":"Francolini G, Allegra AG, Detti B, Cataldo VD, Caini S, Bruni A, et al. Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO). J Clin Oncol. 2023;41:5561\u20138.","journal-title":"J Clin Oncol"},{"key":"1041_CR73","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.2025.43.5_suppl.22","volume":"43","author":"T Niazi","year":"2025","unstructured":"Niazi T, Saad F, Koul R, Thibault I, Chung PWM, Wakil G, et al. Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: a randomized phase II trial (GROUQ-PCS 9). J Clin Oncol. 2025;43:22.","journal-title":"J Clin Oncol"},{"key":"1041_CR74","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/JCO.2025.43.5_suppl.15","volume":"43","author":"C Tang","year":"2025","unstructured":"Tang C, Sherry AD, Hwang H, Francolini G, Livi L, Tran PT, et al. World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): an analysis from the X-MET collaboration. J Clin Oncol. 2025;43:15.","journal-title":"J Clin Oncol"},{"key":"1041_CR75","doi-asserted-by":"crossref","unstructured":"Tang C, Sherry AD, Hwang H, Francolini G, Livi L, Tran PT, et al. World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): an analysis from the X-MET collaboration. J Clin Oncol. 2025;43:15\u201315.","DOI":"10.1200\/JCO.2025.43.5_suppl.15"},{"key":"1041_CR76","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/JU.0000000000003890","volume":"211","author":"TM Morgan","year":"2024","unstructured":"Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, et al. Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part III: salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions. J Urol. 2024;211:526\u201332.","journal-title":"J Urol"},{"key":"1041_CR77","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.radonc.2022.10.005","volume":"176","author":"T Zilli","year":"2022","unstructured":"Zilli T, Achard V, Dal Pra A, Schmidt-Hegemann N, Jereczek-Fossa BA, Lancia A, et al. Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP Delphi consensus. Radiother Oncol. 2022;176:199\u2013207.","journal-title":"Radiother Oncol"},{"key":"1041_CR78","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316.","journal-title":"Lancet"},{"key":"1041_CR79","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","volume":"20","author":"J Calais","year":"2019","unstructured":"Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20:1286\u201394.","journal-title":"Lancet Oncol"},{"key":"1041_CR80","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","volume":"397","author":"AB Jani","year":"2021","unstructured":"Jani AB, Schreibmann E, Goyal S, Halkar R, Hershatter B, Rossi PJ, et al. (18)F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial. Lancet. 2021;397:1895\u2013904.","journal-title":"Lancet"},{"key":"1041_CR81","first-page":"1","volume":"30","author":"CL Deijen","year":"2021","unstructured":"Deijen CL, Vrijenhoek GL, Schaake EE, Vogel WV, Moonen LMF, Pos FJ, et al. PSMA-11-PET\/CT versus choline-PET\/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer. Clin Transl Radiat Oncol. 2021;30:1\u20136.","journal-title":"Clin Transl Radiat Oncol"},{"key":"1041_CR82","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.clgc.2020.08.002","volume":"19","author":"R Mazzola","year":"2021","unstructured":"Mazzola R, Francolini G, Triggiani L, Napoli G, Cuccia F, Nicosia L, et al. Metastasis-directed therapy (SBRT) guided by PET-CT (18)F-CHOLINE versus PET-CT (68)Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness. Clin Genitourin Cancer. 2021;19:230\u20136.","journal-title":"Clin Genitourin Cancer"},{"key":"1041_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.684629","volume":"11","author":"R Wang","year":"2021","unstructured":"Wang R, Shen G, Huang M, Tian R. The diagnostic role of (18)F-choline, (18)F-fluciclovine and (18)F-PSMA PET\/CT in the detection of prostate cancer with biochemical recurrence: a meta-analysis. Front Oncol. 2021;11:684629.","journal-title":"Front Oncol"},{"key":"1041_CR84","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2023.04.025","volume":"84","author":"P Sutera","year":"2023","unstructured":"Sutera P, Song Y, Van der Eecken K, Shetty AC, English K, Hodges T, et al. Clinical and genomic differences between advanced molecular imaging-detected and conventional imaging-detected metachronous oligometastatic castration-sensitive prostate cancer. Eur Urol. 2023;84:531\u20135.","journal-title":"Eur Urol"},{"key":"1041_CR85","doi-asserted-by":"publisher","first-page":"e2452971","DOI":"10.1001\/jamanetworkopen.2024.52971","volume":"8","author":"A Holzgreve","year":"2025","unstructured":"Holzgreve A, Armstrong WR, Clark KJ, Benz MR, Smith CP, Djaileb L, et al. PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with no metastatic disease by conventional imaging. JAMA Netw Open. 2025;8:e2452971.","journal-title":"JAMA Netw Open"},{"key":"1041_CR86","doi-asserted-by":"publisher","first-page":"TPS275","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS275","volume":"41","author":"ZH Rana","year":"2023","unstructured":"Rana ZH, Helie N, Eggleston C, Baker K, Molitoris JK, Ferris MJ, et al. Phase 2 randomized total eradication of metastatic lesions following definitive radiation to the prostate in de novo oligometastatic prostate cancer (TERPs) trial. J Clin Oncol. 2023;41:TPS275\u2013TPS.","journal-title":"J Clin Oncol"},{"key":"1041_CR87","doi-asserted-by":"publisher","first-page":"e628","DOI":"10.1016\/j.clon.2023.07.009","volume":"35","author":"H Abdel-Aty","year":"2023","unstructured":"Abdel-Aty H, O\u2019Shea L, Amos C, Brown LC, Grist E, Attard G, et al. The STAMPEDE2 trial: a site survey of current patterns of care, access to imaging and treatment of metastatic prostate cancer. Clin Oncol (R Coll Radiol). 2023;35:e628\u2013e35.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1041_CR88","doi-asserted-by":"publisher","first-page":"e17111","DOI":"10.1200\/JCO.2025.43.16_suppl.e17111","volume":"43","author":"D Bsteh","year":"2025","unstructured":"Bsteh D, Buckley J, Mitchell S, Ostrow D, Parmentier J-H, Jahan S, et al. Combined genomic profiling of cell-free DNA (cfDNA) and circulating tumor cell DNA (ctcDNA) in S1802, a prospective phase 3 trial for metastatic prostate cancer (mHSPC). J Clin Oncol. 2025;43:e17111\u2013e.","journal-title":"J Clin Oncol"},{"key":"1041_CR89","doi-asserted-by":"publisher","first-page":"TPS283","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS283","volume":"41","author":"BF Koontz","year":"2023","unstructured":"Koontz BF, Karrison T, Pisansky TM, Posadas EM, Ballas LK, Berlin A, et al. NRG-GU011: a phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN). J Clin Oncol. 2023;41:TPS283\u2013TPS.","journal-title":"J Clin Oncol"},{"key":"1041_CR90","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1200\/JCO.2025.43.5_suppl.160","volume":"43","author":"G Francolini","year":"2025","unstructured":"Francolini G, Cataldo VD, Garlatti P, Caini S, Bruni A, Simoni N, et al. PERSIAN trial: early results from a randomized phase II trial testing apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer. J Clin Oncol. 2025;43:160.","journal-title":"J Clin Oncol"},{"key":"1041_CR91","doi-asserted-by":"publisher","first-page":"TPS283","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS283","volume":"43","author":"MP Deek","year":"2025","unstructured":"Deek MP, Shi X, Radwan N, Eggleston C, Baker K, Rana ZH, et al. Phase 2 randomized study of high-risk metachronous oligometastatic prostate cancer with high-risk mutations treated with metastasis-directed therapy and niraparib\/abiraterone acetate plus prednisone (KNIGHTS) trial. J Clin Oncol. 2025;43:TPS283\u2013TPS.","journal-title":"J Clin Oncol"},{"key":"1041_CR92","doi-asserted-by":"publisher","first-page":"TPS5127","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5127","volume":"43","author":"AO Sartor","year":"2025","unstructured":"Sartor AO, Kiess AP, Feng FY, Hadaschik BA, Herrmann K, Iagaru A, et al. PSMA-delay castration (DC): an open-label, multicenter, randomized phase 3 study of [177Lu]Lu-PSMA-617 versus observation in patients with metachronous PSMA-positive oligometastatic prostate cancer (OMPC). J Clin Oncol. 2025;43:TPS5127\u2013TPS.","journal-title":"J Clin Oncol"},{"key":"1041_CR93","doi-asserted-by":"crossref","unstructured":"Sherry AD, et al. Peripheral T-cell priming and micrometastatic disease control with metastasis-directed therapy: multidimensional immunogenomic profiling of oligometastatic prostate cancer in the EXTEND trial. Int J Radiat Oncol Biol Phys. 2023;117:S33\u20134.","DOI":"10.1016\/j.ijrobp.2023.06.299"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01041-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01041-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01041-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:05:13Z","timestamp":1779343513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01041-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1041"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-01041-z","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PTT disclosures: Consulting\/advisory role and Patent with Natsar Pharmaceuticals (Compounds and methods of use in ablative radiotherapy. Patent filed 3\/9\/2012. PCT\/US2012\/028475. PCT\/WO\/2012\/122471) licensed with royalties to Natsar Pharmaceuticals. Consulting\/advisory role and research funding with Astellas Pharma, Reflexion Medical, Bayer Health. Consulting\/advisory role with Bayer, Regeneron, Pfizer, Janssen, AstraZeneca, Lantheus, and Novartis. SKS reports grants from AstraZeneca, Johnson and Johnson, and Regeneron; consulting\/advisory roles for Apricity Health LLC, Arcus Biosciences, Baird, Bayer, Boxer Capital, Breaking Data, Bristol Myers Squibb, Dava Oncology, Dendreon, Hervolution, Johnson & Johnson, Kahr Medical Ltd, Kiniksa Pharmaceuticals, Macrogenics, Merck, NoeticInsight, Novartis, OncLive (owned by Intellisphere, LLC), Pfizer, Portage, Regeneron, Rondo Therapeutics, The Clinical Comms Group, and Vicero. CT disclosure: drug support for trial from Merck, drug and financial support from Noxopharm; Assay and financial support from Myriad Genetics; Royalties and licenses with Wolter Kluwer, Stanford Office of Technology and Licensing; Participation on a data safety monitoring board or advisory board with Bayer, Lantheus, Telix, Molli Surgical, Siemen Healthineer; other support from Elekta, Vision RT. AJA disclosure: Research support (to Duke) from the NIH\/NCI, PCF\/Movember, DOD, Astellas, Pfizer, Bayer, Janssen, BMS, AstraZeneca, Merck, Pathos, Amgen, Novartis; Consulting or advising relationships with Astellas, Pfizer, Bayer, Janssen, BMS, AstraZeneca, Merck, Forma, Celgene, Myovant, Exelixis, GoodRx, Novartis, Medscape, MJH, Z Alpha, Telix.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}